Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Spinocerebellar Ataxias - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Spinocerebellar Ataxias - Pipeline Review, H1 2015', provides an overview of the Spinocerebellar Ataxias's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spinocerebellar Ataxias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinocerebellar Ataxias and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Spinocerebellar Ataxias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Spinocerebellar Ataxias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Spinocerebellar Ataxias pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Spinocerebellar Ataxias - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Spinocerebellar Ataxias pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Spinocerebellar Ataxias Overview 6 Therapeutics Development 7 Pipeline Products for Spinocerebellar Ataxias - Overview 7 Pipeline Products for Spinocerebellar Ataxias - Comparative Analysis 8 Spinocerebellar Ataxias - Therapeutics under Development by Companies 9 Spinocerebellar Ataxias - Therapeutics under Investigation by Universities/Institutes 10 Spinocerebellar Ataxias - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Spinocerebellar Ataxias - Products under Development by Companies 14 Spinocerebellar Ataxias - Products under Investigation by Universities/Institutes 15 Spinocerebellar Ataxias - Companies Involved in Therapeutics Development 16 Baxter International Inc. 16 Bioblast Pharma Ltd. 17 Kissei Pharmaceutical Co., Ltd. 18 Vybion, Inc. 19 Spinocerebellar Ataxias - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 epoetin alfa - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 immune globulin (human) - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 INT-41 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 KPS-0373 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 RNAi Gene Therapy for Machado-Joseph Disease - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 trehalose - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Spinocerebellar Ataxias - Recent Pipeline Updates 39 Spinocerebellar Ataxias - Dormant Projects 43 Spinocerebellar Ataxias - Dormant Projects 43 Spinocerebellar Ataxias - Product Development Milestones 44 Featured News & Press Releases 44 Mar 30, 2015: BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of Its Cabaletta Platform in Spinocerebellar Ataxia Type 3 44 Nov 19, 2014: Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Spinocerebellar Ataxias, H1 2015 7 Number of Products under Development for Spinocerebellar Ataxias - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Spinocerebellar Ataxias - Pipeline by Baxter International Inc., H1 2015 16 Spinocerebellar Ataxias - Pipeline by Bioblast Pharma Ltd., H1 2015 17 Spinocerebellar Ataxias - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 18 Spinocerebellar Ataxias - Pipeline by Vybion, Inc., H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Spinocerebellar Ataxias Therapeutics - Recent Pipeline Updates, H1 2015 39 Spinocerebellar Ataxias - Dormant Projects, H1 2015 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.